Date:8/4/2009

--- ---- ---- ---- Operating expenses: Research and development 5,653 9,151 13,757 15,487 General and administrative 3,435 3,723 6,519 7,906 Restructuring & asset impairment - - 1,056 - ----- ----- ----- ----- Total operating expenses 9,088 12,874 21,332 23,393 ----- ------ ------ ------ Loss from operations (9,088) (12,874) (21,332) (23,393) ------ ------- ------- ------- Other income (expense), net (632) 343 (1,338) 1,007 ---- --- ------ ----- Net loss (9,720) (12,531) (22,670) (22,386) Preferred stock dividends (125) (125) (250) (250) ---- ---- ---- ---- Loss applicable to common shares $(9,845) $(12,656) $(22,920) $(22,636) ======= ======== ======== ======== Loss per share: Basic and diluted $(0.28) $(0.36) $(0.66) $(0.65) ====== ====== ====== ====== Shares used in calculation of loss per share: Basic and diluted 34,712 34,688 34,700 34,684 ====== ====== ====== ====== Condensed Consolidated Balance Sheets (In thousands) June 30, 2009 December 31, 2008 ------------- ----------------- (Unaudited) (Note 1) ASSETS: Cash
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
2. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
3. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
4. Poniard Pharmaceuticals Files Shelf Registration
5. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
6. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
9. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
10. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
11. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer